Lumida
/PROK
⌘K
ProKidney Corp

ProKidney Corp

PROK
$1.80USD-2.17%-0.04 today

MARKET CAP

544.2M

P/E (TTM)

FWD P/E

DAY RANGE

$2 – $2

52W RANGE

$1
$3

AI Summary

Stalk
StalkMedium

PROK remains in a high-confidence Stage 2 advancing phase with strong momentum signals from the recent breakout and structural repair. However, price is currently extended above the 9/21/50 EMAs with RSI and Options Score into overbought territory, increasing the risk of a near-term pullback. The medium-term bias stays bullish based on rising EMAs, volume expansion on advances, and multiple mean-reversion and continuation patterns. Execution is best deferred—await a pullback into the rising 9/21 EMA cluster and the prior breakout area around the former resistance zone for confirmation before initiating exposure.

  • Complete enrollment of 320 patients in Phase 3 PROACT trial; topline data due Q2 2027
  • $181.6 million cash reserves fund operations through mid-2027, enabling pipeline advancement
  • Q2 2026 revenue $0.15 million, missing estimates by 31.8%, highlighting weak commercial dynamics
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2024FY 2025TREND
Sales, Adj.$76,000$893,000
YoY %+1075.0%
P / Sales2177.3x336.0x
EV / Sales1392.0x253.4x
Gross Profit, Adj.$76,000$893,000
YoY %+1075.0%
Margin %100.0%100.0%
EV / Gross Profit1392.0x253.4x
EBITDA, Adj.$-178.2M$-158.4M
YoY %-20.7%+11.1%
Margin %-234531.6%-17741.5%
EV / EBITDA-0.6x-1.4x
EBIT$-183.7M$-165.0M
YoY %-21.2%+10.2%
Margin %-241678.9%-18477.8%
EV / EBIT-0.6x-1.4x
Net Income$-61.2M$-69.0M
YoY %-72.5%-12.7%
Net Margin-80507.9%-7725.2%
EPS (GAAP)-$0.62-$0.52
YoY %-8.8%+16.1%